NSF Responds

I'd like to correct a number of factual errors and misleading statements in "NSF Cuts Back On Faltering Science, Technology Centers" [The Scientist, Feb. 4, 1991, page 1]. The article leaves the impression that Science and Technology Centers (STCs) have become a low priority at NSF. In fact, that is not the case. The STC program is not "faltering." Since your article was researched, nine new centers have been established and others are expected to be announced within the next few weeks. No mas

Written byAlan Levitt
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The STC program is not "faltering." Since your article was researched, nine new centers have been established and others are expected to be announced within the next few weeks.

No massive, "high profile" announcement of the second round of centers was planned (as was the case with the first round) for several reasons. The final fiscal year 1991 budget for research and related activities ultimately meant that NSF was able to allocate only $15 million instead of the $25 million originally planned for the second round of STCs. Foundation officials agonized over whether to reduce the number of new STCs from the 14 finalists to a smaller number, but in the end agreed to attempt to establish all of them.

The finalists were asked to revise their proposals, taking into account the new budget reality. They were provided an opportunity to either downsize their proposals or seek additional funding from ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies